Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers

Danone Research1 site in 1 country600 target enrollmentNovember 2006

ConditionsCommon Infectious Diseases

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Common Infectious Diseases
Sponsor: Danone Research
Enrollment: 600
Locations: 1
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This multicentric, randomized, double-blind and controlled study aims to examine the effect of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel® = tested product) on the incidence of respiratory and gastro-intestinal common infectious diseases (cumulated number of infections during the intervention period: primary criteria) in children aged 3-6 years, attending day care centers.Volunteers received either 200g/day of tested product (N=300) or control product (N=299) for 3-months, followed by a 1-month follow-up.

Registry

clinicaltrials.gov

Start Date

November 2006

End Date

July 2007

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Danone Research

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject whose parents/legal guardians had given written informed consent,
•Male or female, aged 3 to 6 years (upper bound excluded),
•Attending day-care centres or preschools 5 days a week in the Moscow area,
•Subject found medically healthy (in particular, free of respiratory and GI tract symptoms),
•Subject who appreciated dairy products and multi-fruit flavour.

Exclusion Criteria

•Subject whose parents were not reading and writing Russian, or not understanding informed consent or study protocol.
•Subject with allergy or hypersensitivity to milk proteins or dairy foods components (ex: lactose, milk proteins), or with any known food or respiratory allergy.
•Subject presenting a severe evolutive or chronic pathology (Ex: cancer, tuberculosis, Crohn disease, cirrhosis, multiple sclerosis, Type I diabetes...) or any past or actual health condition that could interfere with the outcome of the study (Ex: HIV, Chemotherapy, malabsorption, ulcer, celiac disease, failure to thrive...).
•Subject having experienced any infectious disease during the last 7 days.
•Subject with current diarrhoea or constipation Subject who was frequently using laxatives or who had been using laxatives during the week prior his participation to the study.
•Subject who was under artificial nutrition, had gastro-intestinal surgery or any intervention requiring general anaesthesia the last 2 months prior to his participation to the study.
•Subject with special medicated diet (obesity, anorexia, metabolic pathology, nutritional complementation...) or with eating disorders (anorexia, bulimia...).
•Subject currently receiving, or who had received during the last months, systemic treatment or topical treatment likely to interfere with evaluation of the study parameters: antibiotics, antiseptics, antifungal, corticoids, vaccines, anti-histaminic molecules, non-corticoid antiinflammatory substances, immunosuppressant treatment...
•Subject already enrolled in another clinical study, or currently under an exemption period from a previous study.
•Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.